Novo-Nordisk A/S
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 --
業務概覽 With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
公司地址 Novo Alle 1, Bagsvaerd, DNK, 2880
電話號碼 +45 44448888
傳真號碼 --
公司網頁 https://www.novonordisk.com
員工數量 69505
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Thilde Hummel Bogebjerg Executive Vice President, Enterprise IT and Quality -- 04/02/2026
Ms. Elin Jager Senior Vice President, Chief of Staff and Corporate Strategy and Sustainability -- 04/02/2026
Mr. Jamey Millar Executive Vice President, Us Operations -- 04/02/2026
Mr. Hong Chow Executive Vice President, Product and Portfolio Strategy -- 04/02/2026
Ms. Tania Sabroe Executive Vice President, People, Organisation and Corporate Affairs -- 04/02/2026
Mr. Martin Holst Lange Executive Vice President, Research and Development and Chief Scientific Officer -- 04/02/2026
Mr. Emil Kongshoj Larsen Executive Vice President, International Operations -- 04/02/2026
Mr. Kasper Bodker Mejlvang Executive Vice President, CMC and Product Supply -- 04/02/2026
Mr. Ludovic Helfgott Executive Vice President, Product and Portfolio Strategy -- 04/02/2026
Mr. Maziar Mike Doustdar President and Chief Executive Officer -- 04/02/2026
Mr. Karsten Munk Knudsen Executive Vice President and Chief Financial Officer DKK 9.10M 04/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Stephan Engels Independent Director 04/02/2026
Ms. Britt Meelby Jensen Director 04/02/2026
Ms. Mette Bojer Jensen Director 04/02/2026
Mr. Kasim Kutay Director 04/02/2026
Dr. Cees de Jong Vice Chairman of the Board 04/02/2026
Ms. Liselotte Hyveled Director 04/02/2026
Ms. Elisabeth Dahl Christensen Director 04/02/2026
Mr. Lars Rebien Sorensen Chairman of the Board 04/02/2026
 
所屬ETF (更新日期: 07/03/2026 04:31)
代號 名稱 佔比% ▼ 持有日期
IEFAiShares Core MSCI EAFE ETF0.51%28/02/2026
EFAiShares MSCI EAFE ETF0.25%28/02/2026
VEUVanguard FTSE All-Wld ex-US ETF0.16%31/01/2026
SCHFSchwab International Equity ETF™0.15%28/02/2026
IXUSiShares Core MSCI Total Intl Stk ETF0.10%28/02/2026
VIGIVanguard Intl Div Apprec ETF0.09%31/01/2026
SPDWState Street® SPDR® Ptf Dev Wld exUS ETF0.08%27/02/2026
IQLTiShares MSCI Intl Quality Factor ETF0.07%28/02/2026
IDEViShares Core MSCI Intl Dev Mkts ETF0.07%28/02/2026
EFGiShares MSCI EAFE Growth ETF0.07%28/02/2026
VTVanguard Total World Stock ETF0.05%31/01/2026
CGXUCapital Group International Focus Eq ETF0.05%31/01/2026
BBEUJPMorgan BetaBuilders Europe ETF0.05%27/02/2026
IXJiShares Global Healthcare ETF0.04%28/02/2026
IEURiShares Core MSCI Europe ETF0.03%28/02/2026
DFAIDimensional International Cr Eq Mkt ETF0.03%27/02/2026
JIREJPMorgan International Rsrch Enh Eq ETF0.03%27/02/2026
DBEFXtrackers MSCI EAFE Hedged Equity ETF0.03%24/02/2026
DIHPDimensional International High Pbly ETF0.03%27/02/2026
IHDGWisdomTree Intl Hdgd Qual Div Gr ETF0.03%27/02/2026
 1    2    3    4    5    6    7    8    9    10  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.